For Consumers

Tentative approval of efavirenz, lamivudine and tenofovir disoproxil fumarate tablets

On December 30, 2013 FDA granted tentative approval for efavirenz, lamivudine and tenofovir disoproxil fumarate tablets, 600 mg/300 mg/300 mg, for use alone or in combination with other antiretrovirals for the treatment of HIV-1 infection in adults and adolescents greater than 16 years of age and weighing at least 40 kg.  This triple combination tablet is a product of Cipla Ltd of Mumbai, India.

The application was reviewed under the expedited review provisions of the President’s Emergency Plan for AIDS Relief (PEPFAR).

"Tentative approval" means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but is not eligible for marketing in the U.S. because of existing patent protections. Tentative approval does, however, make the product eligible for purchase outside the United States under the PEPFAR program.

Richard Klein
Office of Health and Constituent Affairs
Food and Drug Administration

Kimberly Struble
Division of Antiviral Products
Food and Drug Administration

Steve Morin
Office of Health and Constituent Affairs
Food and Drug Administration

 

 

Page Last Updated: 09/16/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.